Risk factors for late-onset lower limb lymphedema after gynecological cancer treatment: A multi-institutional retrospective study

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Masato YoshiharaAkio Hirota

Abstract

Late-onset lower limb lymphedema (LLL) is a significant clinical challenge for physicians dealing with patients that undergo treatment involving the pelvic cavity. We aimed to clarify the prevalence of and risk factors for late-onset LLL after treatment for gynecological cancer. We conducted a multicenter retrospective study using records of cases in which LLL diagnosed by physical findings and measurement of limbs girths. Patients with LLL after treatment for uterine cervical, endometrial, and ovarian cancer were sequentially enrolled. We examined the timing of LLL onset and the associations between the time to onset and clinical characteristics, including age, type of cancer, lymphadenectomy sites, and performance of radiotherapy. We also investigated the risk factors for late-onset LLL and their effects on the cumulative incidence of late-onset LLL. In total, 711 patients fulfilled the required criteria. Mean age of was 50.2 years old and median follow-up period was 5.05 years. More than half of them (50.5%) presented with LLL ≥5 years after undergoing treatment for gynecological cancer. A substantial number of patients (29.4%) developed LLL ≥10 years after undergoing treatment for gynecological cancer. Being aged <50 years ...Continue Reading

References

Aug 25, 2006·Annals of Plastic Surgery·Meisei TakeishiHiroshi Sasaki
Jan 8, 2011·International Journal of Clinical Oncology·Yoko OhbaNoriaki Sakuragi
Mar 26, 2011·Aesthetic Plastic Surgery·Roberto BracagliaMarco D'Ettorre
Mar 9, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jin Hwi KimSoo Young Hur
Mar 16, 2013·Aesthetic Plastic Surgery·Roberto BracagliaDamiano Tambasco
Mar 19, 2014·Gynecologic Oncology·Ingrid J RowlandsUNKNOWN Australian National Endometrial Cancer Study Group
Apr 24, 2014·Aesthetic Surgery Journal·Roberto BracagliaDamiano Tambasco
Jul 9, 2014·Obstetrics and Gynecology·Kathleen J YostSean C Dowdy
Feb 28, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Hitoshi HareyamaKazuhiko Okuyama
Jun 5, 2015·The British Journal of Surgery·M CariatiA D Purushotham
Jul 6, 2015·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Se Ik KimSang-Yoon Park
Mar 5, 2016·Gynecologic Oncology Reports·Elizabeth E HoppDenise S Uyar
May 18, 2016·The Breast : Official Journal of the European Society of Mastology·S L KilbreathK Gaitatzis
Jul 12, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Eun Young KiSoo Young Hur
Oct 14, 2017·Aesthetic Surgery Journal·Stefano GentileschiMarzia Salgarello
Aug 11, 2019·Microsurgery·Stefano GentileschiGiorgia Garganese

❮ Previous
Next ❯

Citations

Nov 17, 2020·The Journal of Obstetrics and Gynaecology Research·Jorge Cea GarcíaMaría Del Carmen Rubio Rodríguez
Oct 7, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Madelene WedinUNKNOWN LASEC study group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.